Cavinton

Vinpocetine increases cerebral metabolism, boosting glucose and O2 consumption; it improves the brain's tolerance to hypoxia and shifts glucose metabolism toward the more energetically favourable aerobic pathway, though the anaerobic pathway is increased as well. It raises ATP concentration and the ATP to AMP ratio in the brain and elevates cerebral levels of norepinephrine, dopamine and serotonin.

The drug considerably improves cerebral microcirculation by inhibiting platelet aggregation, lowering pathologically increased blood viscosity, and increasing erythrocyte deformability. It also helps carry O2 into the tissues by reducing the O2 affinity of erythrocytes.

Vinpocetine selectively and markedly increases cerebral blood flow and the brain's share of cardiac output, and it lowers cerebral vascular resistance without affecting systemic circulation, including blood pressure, heart rate, cardiac output and total peripheral resistance. It does not produce a steal phenomenon; instead, it mainly improves blood supply to injured and ischaemic areas while leaving blood flow in healthy areas unchanged, an effect known as inverse steal. It also further increases blood flow that is already raised as a result of hypoxia.

Vinpocetine should not be used during pregnancy or while breastfeeding (lactation).

Keep Vinpocetine in a cool, dry place, away from light and moisture.